ARCHIVES

DeVita Resigns As No. 2 At Sloan-Kettering To “Pursue Clinical Research,” Hospital Says

This article is from The Cancer Letter archive.

Vol. 17 No. 22 | May 31, 1991

Download PDF Visit The Full Archive

Related Articles

NCAB, President’s Cancer Panel honor the late Paul Calabresi.

June 11, 2004

Avastin-Zybrestat Combination Increases Progression-Free Survival in Phase II Trial

March 28, 2014

Ohio State to study center expansion.

September 26, 2003

No Cancer Letter For Next Two Weeks

August 30, 1991

Scientists, Advocates Voice Objections To von Eschenbach’s Conflicts, 2015.

November 22, 2006

FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival.

March 5, 2004